Expression of Cre recombinase as a reporter of signal transduction in mammalian cells  by Mattheakis, Larry C et al.
Expression of Cre recombinase as a reporter of signal
transduction in mammalian cells
Larry C Mattheakis, Susan E Olivan, Jennifer M Dias* and Jeffrey P Northrop
Background: Cell-based reporter assays, which rely on a reporter gene under
the control of a regulated promoter, are widely used to screen chemical libraries
for novel receptor ligands. Here, we describe a reporter system that is based on
ligand-induced DNA recombination to express the reporter gene. This system
converts a transient activation of a signal transduction pathway into an
amplified, constitutive and heritable expression of the reporter gene. 
Results: We constructed gene fusions of Cre recombinase and mammalian
promoters regulated by calcium, nuclear receptors or cyclic AMP. Reporter
systems, comprising a Cre gene fusion and a loxP/reporter gene, were used to
study the kinetics and dose responses to compounds that activate or inhibit the
corresponding signal transduction pathway. We compared these reporters with
conventional reporter systems in which the reporter gene is under the direct
control of the responsive promoter. Reporter gene expression of the Cre
reporters was greater than that of conventional reporters and could be
measured more than a week after adding the stimulus. For all pathways studied
here, the dose responses of the Cre reporters are nearly identical to those of
conventional reporter systems.
Conclusions: We have shown that Cre recombinase can be regulated by a
variety of signal transduction pathways. It should therefore be possible to use
receptor ligands to induce phenotypic conversion of mammalian cells for use in
a variety of applications. One such application is high-throughput screening,
and we developed loxP/luciferase reporter genes that provide an amplified and
sustained luminescent response.
Introduction
The use of reporter genes is a powerful and facile method
for studying signal transduction pathways and for discover-
ing new receptor ligands. To screen ligands, reporter
genes are placed under the control of a regulated promoter
in cell lines expressing a cell-surface receptor or intracellu-
lar target. Binding of an active compound to the target
stimulates a signal transduction cascade, resulting in
expression of the reporter gene. The use of such engi-
neered cell lines for screening offers significant advan-
tages over traditional competition binding assays,
including the potential to identify active compounds that
do not compete for binding with the natural ligand, and to
distinguish receptor agonists from antagonists [1,2].
To adapt reporter-gene technology to drug discovery, it
has become necessary to develop high-throughput assays
because the recent introduction of combinatorial chemical
libraries has resulted in a vast increase in the number of
compounds to be screened [3,4]. A common high-through-
put screening strategy is to miniaturize the assay by reduc-
ing the assay volume and increasing the density of wells
per assay plate. Miniaturization results in fewer cells per
well and a decrease in the signal strength, which can lead
to potential problems for reporter genes under the control
of weak promoters. A method for amplifying reporter gene
expression would therefore be desirable for screening
large numbers of compounds in a miniaturized format. 
In addition to limited signal strength, the duration of
reporter gene expression can be short lived, depending on
the receptor type, signal transduction pathway and
reporter protein stability. Factors such as receptor desensi-
tization or compound degradation may also limit the time
available for measuring a reporter gene response. Depend-
ing on the assay format, it may therefore be desirable to
convert a transient activation of a promoter into a perma-
nent and constitutive expression of the reporter gene. 
Here we describe a strategy in which transient activation
of a signal transduction pathway leads to an amplified,
constitutive and heritable expression of a reporter gene.
The method relies on DNA recombination by the Cre
recombinase of bacteriophage P1. In mammalian cells, Cre
can efficiently catalyze reciprocal DNA recombination
between pairs of loxP sites [5]. Each loxP site consists of
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two 13 base pair (bp) inverted repeats flanking an 8 bp
nonpalindromic core region [6]. If two directly repeated
loxP sites flank a segment of DNA, Cre catalyzes deletion
of the intervening sequence and one of the loxP sites. 
The Cre/loxP system has become a powerful method for
introducing precise genetic modifications in the mouse
[7]. For example, specific gene ablation is possible by
mating a transgenic mouse carrying a target gene flanked
by loxP sites with a transgenic mouse carrying Cre under
the control of a tissue-specific promoter. The target gene
is deleted in those tissues of the double transgenic mouse
in which the cre gene has been expressed. 
To control recombination temporally, the cre gene has
been placed under the control of the synthetic tetracycline
promoter [8], or fused to the ligand-binding domain of a
steroid receptor [9–11]. In the latter example, binding of
ligand to the steroid receptor activates the recombinase
function of the fusion. 
In a previous study, we fused Cre to the ligand-binding
domain of the glucocorticoid receptor and constructed a
luciferase reporter gene that expresses luciferase after
Cre-mediated recombination [12]. This reporter system,
unlike a transcriptional reporter using the mouse
mammary tumor virus promoter (MMTV), functions as a
binding assay, and can be used to screen for steroid recep-
tor agonists or antagonists. 
To expand the use of the Cre/loxP system for screening
receptor ligands, we placed the cre gene under the tran-
scriptional control of the native MMTV, synthetic nuclear
factor of activated T cells (NFAT), or cyclic AMP-respon-
sive element (CRE)-dependent promoters. Our aim was
to show the general utility of the Cre/loxP system for three
distinct classes of signal transduction pathways: nuclear-
receptor-mediated, calcium-regulated and cyclic-AMP-
regulated pathways. Here we show the kinetics and dose
responses of these gene fusions to compounds that acti-
vate or inhibit the corresponding signal transduction path-
ways. We discuss the results in the context of using these
gene fusions in screening for receptor ligands and other
transcriptional activators, and of their potential use as tools
to study signal transduction pathways in development. 
Results
Regulation of Cre by the NFAT signaling pathway
The transcription factor NFAT is activated in lymphoid
cells in response to a rapid increase in the intracellular
calcium concentration (reviewed in [13]). To study regula-
tion of Cre recombinase by NFAT, we constructed the
plasmid NFAT–Cre, which contains three copies of the
minimal NFAT-binding site and an IL-2 minimal pro-
moter. We also constructed the loxP/luciferase reporter
plasmid pLM255 (Figure 1). Plasmid pLM255 does not
express luciferase because a stop sequence, upstream of
the luciferase gene, inhibits read-through transcription
from the cytomegalovirus (CMV) promoter [14,15]. Two
directly repeated loxP sites flank the stop sequence.
Cre-mediated recombination excises the stop sequence
and permits luciferase expression to be driven by the
strong CMV promoter. To select for the presence of
pLM255, we inserted the puromycin acetyltransferase
(pac) gene adjacent to the stop sequence. The pac gene is
excised by unregulated expression of Cre, so continuous
growth in the presence of puromycin should select against
clones that recombine in the absence of NFAT activation. 
To test regulation of this system in a transient transfection
assay, we cotransfected Jurkat cells with plasmids
NFAT–Cre and pLM255. A control plasmid, NFAT–Luc,
that expresses luciferase directly from the NFAT-depen-
dent promoter, was used in a separate transfection. As
shown in Table 1, luciferase activity is weakly stimulated
when cells are incubated with the calcium ionophore iono-
mycin or the ionomycin or phorbol myristate acetate (PMA)
alone. Costimulation of cells with PMA and ionomycin
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Figure 1
Structure of the loxP/luciferase reporter
plasmid pLM255 and activation of luciferase
expression by recombination. The open
arrows indicate the positions of PCR primers
used to amplify the 750 bp fragment
corresponding to recombined pLM255. 
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(P/I) results in a dramatic increase in luciferase expression
for both transfected populations, but the NFAT–Cre popu-
lation has a higher stimulated activity (nearly 50-fold at this
time point of 20 hours) than NFAT–Luc. This is probably
due to stronger expression of luciferase from the CMV pro-
moter than that from the NFAT-dependent promoter, and
indicates that the Cre system can amplify expression of
a reporter gene. Although the nonstimulated level of
luciferase is higher in the NFAT–Cre cell population,
the fold stimulation is actually higher than in the
NFAT–Luc population.
To study regulation of Cre in a stable clone, we trans-
fected Jurkat cells with pLM255 and selected a
puromycin-resistant population. The selected population
was subsequently transfected with the NFAT–Cre–neo
plasmid, carrying a neomycin resistance gene, and a
puromycin- and neomycin-resistant population was
selected. Clones were isolated by limiting dilution and
tested for luciferase regulation by incubating with P/I.
Clones ranged in phenotype from low activity regardless
of stimulation to very high constitutive activity (data not
shown). Clones that showed high inducible activity and
low background were chosen for further analysis.
The kinetics of luciferase expression during incubation
with ionomycin and PMA of a selected NFAT–Cre clone
was compared with that of a control Jurkat clone carrying
the NFAT–Luc plasmid. Figure 2 shows that the luciferase
activity of the NFAT–Luc clone peaks at 6 hours, and
declines dramatically after 24 hours. Luciferase activity of
the NFAT–Cre clone, however, increases almost linearly
during the 24 hour time period. By 24 hours, the luciferase
activity produced by the NFAT–Cre cells is 7–8-fold
greater than the peak luciferase activity from the
NFAT–Luc cells. These results indicate that the pattern of
luciferase gene expression differs markedly between
NFAT–Cre and NFAT–Luc cells, and that amplification
of gene expression in the Cre system is a delayed process. 
To study the kinetics of luciferase gene expression over
longer time periods, the NFAT–Cre and NFAT–Luc
clones were stimulated for 7 hours, washed to remove P/I,
and grown in medium lacking puromycin. Aliquots were
removed at various times, and the luciferase activities of
the stimulated and nonstimulated cells were compared.
The activity of NFAT–Luc cells appears near maximal at
7 hours after stimulation as previously observed, and
declines to background levels by 2 days (Figure 3a). The
NFAT–Cre clone, however, continues to express
luciferase 7 days following stimulation (Figure 3b).
Expression of luciferase from the NFAT–Cre clone
reaches a maximum of 12-fold greater than the peak
activity of the NFAT–Luc cells at 19 hours, then declines
and reaches a steady-state level after 3 days. The decline
in luciferase activity from the NFAT–Cre cells probably
results from removal of PMA during the wash step, as
PMA is a strong stimulant of the CMV promoter in Jurkat
cells (data not shown). These results indicate that expres-
sion of Cre through NFAT induction results in constitu-
tive expression of a reporter gene.
To confirm that expression of Cre results in DNA recombi-
nation, we analyzed genomic DNA by using the poly-
merase reaction (PCR). A 750 bp PCR fragment
corresponding to the recombined form of pLM255 was
generated from NFAT–Cre cells incubated with ionomycin
and PMA in far greater abundance than in the nonstimu-
lated cells. As a control, cells carrying the NFAT–Luc
reporter do not contain the 750 bp fragment (Figure 4).
The presence of small amounts of recombined pLM255 in
the nonstimulated cells is consistent with the slightly
increased nonstimulated luciferase levels in these cells as
compared with NFAT–Luc cells (Figure 2). This basal
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Figure 2
Time course of luciferase expression in stable Jurkat clones NFAT–Cre
(triangles) or NFAT–Luc (squares). Cells were incubated in the
presence of 2 µM ionomycin and 20 ng/ml PMA, and luciferase activity
was measured at various times as indicated. 
0 5 10 15 20 25
0
500,000
1,000,000
1,500,000
2,000,000
2,500,000
Lu
ci
fe
ra
se
 a
ct
iv
ity
 (c
ps
)
Time (h)
Chemistry & Biology
Table 1
Luciferase activity of Jurkat cells after transient transfection
with NFAT–Cre/pLM255 or NFAT–Luc plasmids.
NFAT–Luc NFAT–Cre/pLM255
Nonstimulated 8.5 × 102 1.7 × 104
Ionomycin 2.6 × 103 (3) 3.1 × 104 (2)
PMA 3.4 × 103 (4) 4.8 × 104 (3)
Ionomycin + PMA 4.4 × 104 (52) 2.1 × 106 (124)
Cells were stimulated as indicated for 20 h. Numbers in parentheses
refer to x-fold stimulation relative to nonstimulated controls.
signal probably represents either a small proportion of cells
that have recombined, or the presence of a least one recom-
bined pLM255 construct out of multiple integrants in the
NFAT–Cre clone. 
We next compared the dose responses of the clones to iono-
mycin or to the immunosuppressant cyclosporin A (CsA),
which blocks translocation of NFAT to the nucleus [16].
Figure 5a shows that the EC50 value of ionomycin is essen-
tially the same for both NFAT–Cre and NFAT–Luc cells
(1.2 µM and 1.6 µM, respectively), but that the shapes of
the curves are different (the NFAT–Cre dose-response
curve is steeper). For CsA, the inhibition curves are similar
in shape, and the IC50 values are essentially the same
(12 ng/ml and 10 ng/ml for NFAT–Luc and NFAT–Cre,
respectively, Figure 5b). The NFAT–Cre reporter system
therefore gives the same EC50 for agonist and IC50 for
antagonist as the conventional NFAT–Luc reporter system. 
Regulation of Cre by the MMTV promoter
The MMTV promoter is activated by binding of a steroid
receptor–ligand complex, such as the glucocorticoid recep-
tor (GR) bound to the ligand dexamethasone (Dex), to
specific sites on the DNA [17]. To study regulation of Cre
by the MMTV promoter, we constructed plasmids
MMTV–Cre and MMTV–Luc, which contain the MMTV
long terminal repeat promoter regulating transcription of
Cre and luciferase, respectively. 
The time course of luciferase gene expression and dose
response of dexamethasone was measured by transient
transfections of CHO cells. Cells transfected with an
expression construct for human GR and with either
MMTV–Cre plus the loxP/luciferase reporter plasmid
pLM255, or with the MMTV–Luc plasmid, were stimu-
lated with Dex and luciferase activities were measured at
various times. The time course of luciferase expression
from the MMTV promoter, in contrast to that from the
NFAT-dependent promoter, appears similar in both the
MMTV–Cre and MMTV–Luc systems (Figure 6a). Both
reporter systems show similar delayed kinetics, and
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Figure 4
PCR analysis of genomic DNA before and after expression of Cre in
Jurkat cells. Jurkat clones NFAT–Luc and NFAT–Cre were incubated in
the presence (S) or absence (N) of 20 ng/ml PMA and 2 µM
ionomycin for 24 h, and genomic DNA was isolated using a
PuregeneTM kit (Gentra systems, Minneapolis, MN). PCR primers
(indicated in Figure 1) were used to amplify a 750 bp fragment
corresponding to recombined pLM255. PCR conditions included
varying the cycle number and Mg2+ concentration as indicated. Lane M
indicates molecular weight standards. 
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Figure 3
Time course of luciferase expression in Jurkat clones after removal of
PMA and ionomycin (P/I). Jurkat clones (a) NFAT–Luc or
(b) NFAT–Cre were incubated for 7 h in the presence (P/I) or absence
(NS) of 20 ng/ml PMA and 2 µM ionomycin. Cells were then washed,
cultured in growth medium lacking puromycin, and luciferase activities
were determined and normalized to cell number at the indicated times
after addition of stimulus. 
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luciferase expression is not yet maximal after 24 hours of
stimulation. The amplification of luciferase expression
using the Cre/loxP system is less pronounced for the
MMTV promotor than for the NFAT-dependent pro-
moter (threefold at 24 hours). This may reflect the intrin-
sic relative strengths of these two promoter systems.
We measured the dose response of Dex and found the
EC50 values for MMTV–Cre and MMTV–Luc to be
similar at 4 nM and 2 nM, respectively (Figure 6b). Unlike
the NFAT system, the shape of the dose-response curves
is similar between the MMTV–Cre and MMTV–Luc
reporters. Differences between recombinase-based and
conventional reporter systems in the kinetics of reporter
gene expression and shape of the dose-response curve are
therefore dependent on the promoter and signal transduc-
tion pathway being studied. 
One additional advantage of the Cre/loxP system is the
potential to amplify a short signal pulse into one that can
be measured (albeit at a later time). To determine how
long Cre must be synthesized for recombination to occur,
we used the glucocorticoid receptor antagonist RU486,
which competes with Dex for receptor binding and blocks
transcription. CHO cells transfected with MMTV–Cre/
pLM255 or MMTV–Luc plasmids were stimulated with
Dex, washed, and RU486 was added at various times.
Figure 7a shows that 24 hours of Dex treatment results in
the usual induction and signal amplification in the
Cre/loxP system, whereas RU486 alone for 24 hours results
in a much smaller, but significant, induction. The induc-
tion by RU486 alone may be caused by RU486 acting as a
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Figure 5
Dose responses of Jurkat clones NFAT–Luc (squares) and NFAT–Cre
(triangles) to (a) ionomycin in the presence of 20 ng/ml PMA, or
(b) cyclosporin A (CsA) in the presence of 1 µM ionomycin. NFAT–Luc
cells were stimulated for 6 h and NFAT–Cre cells were stimulated for
24 h. For visual clarity, data are expressed as counts per second (cps)
of luciferase activity for the NFAT–Cre cells and as cps × 10 for the
NFAT–Luc cells. Therefore, the actual cps for the NFAT–Luc cells is
tenfold less than indicated by the scale. EC50 and IC50 values and
slopes were calculated using a nonlinear least squares regression to a
four-parameter logistic equation [35].
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Figure 6
Luciferase expression in CHO cells transiently transfected with
MMTV–Cre/pLM255 (triangles) or MMTV–Luc (squares) plasmids.
(a) Time course of luciferase expression by cells incubated with 1 µM
dexamethasone (Dex). (b) Dose-response curve for Dex. Cells were
stimulated for 24 h. Luciferase activity is presented as counts per
second (cps) normalized to β-galactosidase activity.
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partial agonist of the MMTV promoter, and small amounts
of Cre may be sufficient to recombine the luciferase
reporter gene. 
To vary the amount of Cre, RU486 was added at various
times after addition of Dex. In the MMTV–Luc system,
addition of RU486 at 8 hours after addition of Dex
resulted in less than 10% of the luciferase activity
observed for cells incubated with Dex alone (Figure 7b).
The MMTV–Cre system, however, resulted in nearly 60%
maximal activity after 8 hours of Dex stimulation, although
the partial agonist activity of RU486 may also be contribut-
ing to the synthesis of Cre under these conditions. It
therefore appears that limited transcription of Cre results
in nearly maximal induction of luciferase. 
Regulation of Cre by the cyclic AMP response pathway
The elevation of the intracellular cyclic AMP concentra-
tion results in phosphorylation of the transcriptional trans-
activator CREB, which is then competent to bind the
cyclic AMP response element (CRE) and stimulate tran-
scription [18]. To study regulation of Cre recombinase by
the cyclic AMP response pathway, we constructed plasmid
6CRE–Cre that contains the Cre gene under the transcrip-
tional control of six CREs and a minimal thymidine kinase
promoter (6CRE promoter). Plasmid 6CRE–Cre also
carries a hygromycin selectable marker for selection. 
To isolate stable clones, plasmid 6CRE–Cre and the
loxP/luciferase reporter plasmid pLM255 were cotrans-
fected into CHO cells expressing the cholecystokinin B
(CCKb) receptor, and selected in medium containing
hygromycin and puromycin. The CCKb receptor is a
G-protein-coupled receptor that normally couples to Gq,
resulting in production of IP3 and release of calcium from
intracellular stores [19]. We found, however, that the
CCKb receptor in CHO cells also couples to GS-proteins,
and causes an increase in the intracellular cyclic AMP con-
centration after binding of the ligand CCK8 (T. Chernov-
Rogan and L.M., unpublished observations). Individual
clones were isolated using a fluorescence-activated cell
sorter (FACS) and tested for luciferase production after
incubation with CCK8. The frequency of CCK8-regulated
clones was rare (only three clones out of ~100 screened).
The clone with the highest induced activity of luciferase
(6CRE–Cre 2D7) was chosen for further study. As a
control, we isolated a CHO clone expressing the CCKb
receptor and carrying the luciferase gene under the control
of the 6CRE promoter (6CRE–Luc 3B6). 
The time course of luciferase expression was determined
by incubating the 6CRE–Cre and 6CRE–Luc clones with
the ligand CCK8 for 24 hours. As was observed for the
NFAT–Cre and MMTV–Cre reporter systems, the
luciferase activity of the 6CRE–Cre clone increases
throughout the 24 hour time period, whereas the activity
of 6CRE–Luc peaks at 8 hours and returns to near back-
ground levels by 24 hours (Figure 8a). The recombination
rate in the 6CRE–Cre clone appears to be tightly regu-
lated, because luciferase activity in the absence of ligand
is very low (Figure 8a). The activity of 6CRE–Cre at
24 hours is only 30% higher than the peak activity of
6CRE–Luc at 8 hours. Thus, although absolute amplifica-
tion of reporter expression in the CRE-based promoter
system is similar to the MMTV promoter system, the time
course of reporter induction is similar to the NFAT-
dependent promoter system. 
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Figure 7
Effect of the receptor antagonist RU486 on luciferase expression in
CHO cells transiently transfected with MMTV–Cre/pLM255 or
MMTV–Luc plasmids. (a) Cells were incubated in the absence (NS) or
presence of 1 µM RU486 or 1 µM dexamethasone (Dex) for 24 h.
Luciferase activities were normalized to β-galactosidase activity.
(b) Cells were incubated with 5 nM Dex, and RU486 was added (final
concentration 1 µM) at the times indicated. After 24 h, luciferase
activities were measured. Luciferase activities were normalized to
β-galactosidase activity and expressed as a percentage of the signal
obtained with Dex alone for 24 h. RU, RU486 treatment alone for 24 h.
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To study the regulation of 6CRE–Cre at longer time inter-
vals, we incubated cells in the presence or absence of CCK8
ligand for 24 hours, then washed to remove ligand, and
further cultured the cells for 6, 8 and 9 days. Even at 9 days
after exposure to ligand, the activity of the stimulated cells
is more than tenfold greater than that of the unstimulated
cells (Figure 8b). These results are consistent with those
obtained with the NFAT–Cre clone, and demonstrate that
the Cre system is able to record signal transduction events
occurring more than a week after stimulation with ligand.
Dose-response curves were constructed and the EC50 value
of the ligand CCK8 was measured at 21 nM for the
6CRE–Cre clone and 4 nM for the 6CRE–Luc clone
(Figure 9). These results suggest that minor differences in
the reporter response curves between conventional and the
Cre/loxP systems can occur, and may depend on the partic-
ular signaling system and cell clones used. 
Discussion
Cre recombinase has been expressed in a variety of cell
types and is a powerful tool for introducing precise genetic
alterations in a genome [20–22]. In this study, we placed
Cre under the control of several promoters that are regu-
lated by distinct signal transduction pathways. We devel-
oped reporter systems for studying the regulation of Cre by
these pathways, and compared them with conventional tran-
scriptional reporter systems for assaying receptor ligands.
To screen for receptor ligands, the Cre/loxP reporters
described here have potentially two important advan-
tages over conventional transcriptional reporters. First,
the Cre/loxP system can amplify expression of the
reporter gene, because any strong promoter can be used
to transcribe the reporter. The extent of amplification,
however, appears to depend somewhat on the particular
signal transduction pathway, but a variety of strong pro-
moters can be selected to gain optimal amplification in a
given cell type. Second, expression of the reporter gene
is constitutive once cells have undergone recombination.
This allows reporter gene expression to be assayed days
or weeks after addition of the ligand. In theory, if the
background rate of recombination is negligible, the
induced reporter signal has an unlimited time frame of
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Figure 8
Time course of luciferase expression in CHO clones expressing the
CCKb receptor. (a) Clones 6CRE–Cre (solid line) or 6CRE–Luc
(dashed line) were incubated in the presence (closed circles) or
absence (open circles) of 0.5 µM CCK8 for 24 h, and luciferase
activities measured at the indicated times. (b) Clone 6CRE–Cre was
incubated in the presence (solid bar) or absence (open bar) of 0.5 µM
CCK8 for 24 h, then washed to remove ligand and cultured for the
indicated days. Luciferase activity was determined and normalized to
total cell number. 
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Figure 9
Dose-response curves of 6CRE–Cre (triangles) and 6CRE–Luc
(squares) clones after incubating with the CCKb agonist CCK8 for
24 h and 6 h, respectively.
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readability because expression of the reporter gene is a
heritable trait. 
The utility of the Cre/loxP system for screening may ulti-
mately depend on the screening format. For example, it
may be possible to assay reporter activity of a single cell
by incubating with compound and waiting for the signal to
amplify exponentially during cell growth. Other screening
formats, such as compounds overlaid on cells embedded in
agar [23], may benefit from a Cre-based system because
the diffusion of a compound through agar can limit the
time cells are exposed to an effective concentration of the
compound. A short exposure time to the compound may
only induce Cre transcription in a few cells, but this may
be sufficient to trigger recombination and therefore ampli-
fication of expression of the reporter gene. It may also be
possible to substitute luciferase with a selectable marker
and use growth selection to report binding of a ligand.
The Cre/loxP system may therefore be most useful in
screening formats that are not suitable for the transient
signals generated by conventional reporter systems. 
An important feature of any cell-based reporter system is
the dose response of receptor agonists and antagonists.
The Cre reporters are two-component systems comprised
of the recombinase and the loxP reporter, yet they appear
to give similar EC50 values to the conventional systems
for the three different promoters studied here. The EC50
value is therefore determined by transcription initiation
of the promoter responding to the stimulus, and appears
to not be greatly affected by other downstream events
innate to the Cre/loxP system or by parameters that can
affect reporter gene expression, such as mRNA stability
or translation initiation.
Reporter gene expression by recombination is a multistep
process, and increasing luciferase activity in the Cre
reporter systems is probably caused by an increasing per-
centage of cells within the population undergoing recombi-
nation and thus expressing the reporter gene. In
NFAT–Cre cells, two potential concentration thresholds,
NFAT and recombinase, probably need to be overcome to
recombine the reporter gene. Transcription from an
NFAT-dependent promoter has previously been shown to
respond only to a tight threshold of NFAT concentration in
the nucleus [24]. This property of two thresholds may be
responsible for the steeper ionomycin dose-response curve
for NFAT–Cre cells than that for NFAT–Luc cells. In con-
trast, the shape of the dose-response curves in the MMTV
and 6CRE systems are similar in the Cre-based and corre-
sponding traditional reporters. This is probably due to
intrinsic properties of these promoters as compared with
the NFAT-dependent promoter. All of the Cre reporters,
however, have a delay in reporter gene expression, presum-
ably caused by the extra time needed for Cre to translocate
into the nucleus and recombine the loxP sites.
A second potential application of Cre-based reporters is
their use in the study of signal transduction pathways
during development. Current reporter constructs used in
transgenic animals, for instance, provide a readout signal
only when there is an actual transcriptional stimulus and
do not track the fate of cells afterwards. The ability to
convert a transient signal into a permanent readout of
gene expression may make Cre-based reporter systems
valuable in this context. For example, the role of
NFAT-dependent signaling during cell fate decisions in
thymic development could be studied by using
NFAT–Cre and a visible loxP-based reporter gene such as
green fluorescent protein. Moreover, the effects of a drug
or pathogen on developmental processes could be studied
weeks or months after a single exposure.
The success of isolating suitable stable cell lines carrying
Cre gene fusions is largely dependent on the basal activity
of the promoter and signal transduction pathway being
studied. We used puromycin selection to isolate stable
clones, because unregulated expression of Cre results in
excision of the puromycin resistance cassette and elimina-
tion of these clones from the population. We found that
with promoters having low basal activity, such as NFAT in
Jurkat cells, it was relatively easy to find many clones that
were appropriately regulated. In contrast, only a few
useful clones of the 6CRE–Cre reporter were isolated,
presumably because relatively high intracellular cAMP
concentrations results in high basal activity of this pro-
moter unless integration occurs in a particularly quiescent
area of the genome. Cre recombinase is a stable enzyme
[25], and it is likely that small amounts can eventually cat-
alyze recombination. Our results are consistent with this
hypothesis because reporter expression still occurs in the
MMTV–Cre system, even if transcription is blocked by
RU486 soon after induction with Dex. 
Another method for isolating a stable clone carrying Cre
under the control of a leaky promoter may be to mutage-
nize the loxP sites. Previous results have shown that the
rate of Cre-mediated recombination is dependent on the
nucleotide sequence of the loxP sites [26,27]. It should be
possible, therefore, with a library of loxP sites, to screen
the library using puromycin selection for sites that are
resistant to the background levels of Cre. Thus, one could
find classes of loxP sites whose recombination potential is
matched to the basal activities of different classes of pro-
moters. Such improvements could extend the use of Cre
reporters to include many additional promoters and signal
transduction pathways. 
Significance
We have developed a system for regulating DNA recom-
bination in mammalian cells using chemical ligands. The
Cre reporter system links signal transduction to DNA
recombination. Receptor ligands can therefore be used to
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alter mammalian cell phenotypes. The Cre reporters can
also be used to study signal transduction under conditions
that are not suitable for the transient signals generated by
conventional reporter systems. For ultra-miniaturized
screening formats, it may be possible to use the Cre
reporter system to measure effects of ligands on single
cells. An active compound will trigger a genetic switch in
a single Cre reporter cell to express the reporter gene, and
inheritance of the reporter gene phenotype will cause the
reporter signal to amplify through cell division. If the
background rate of recombination remains low, there is
also no time limit for assaying the cells after compound
addition. Thus, compared with conventional reporter
systems, the Cre reporters offer the advantage of signal
amplification and an unlimited time frame for signal
detection. Other applications of Cre reporters may
include studying the fate of transcribed genes during
development. The ability to convert a transient activation
of a signal transduction pathway into a permanent
readout of gene expression means that a compound’s
effect on transcription could be tracked for weeks or
months after a single exposure.  
Materials and methods
Plasmid constructions
To construct the loxP luciferase reporter plasmid pLM255, plasmid
pBS302 [15] was cut with EcoRI/ScaI and the 1.5 kb fragment contain-
ing the loxP/stop/loxP cassette was ligated to the EcoRI/BbsI sites of
pCMVSport 1 (Life Technologies, Gaithersburg, MD) to generate
pCLSport 1. Plasmid pSRα lux (ARI 1819) was digested with Not I/XhoI
and the 1.7 kb fragment containing the luciferase gene was ligated to the
Not I/Sal I sites of pCLSport 1 to generate pLM252. The 1.1 kb pac gene
and SV40 promoter from pPUR (Clontech, Palo Alto, CA) was amplified
using PCR and ligated to the Afl II sites of pLM252 to generate pLM255. 
The NFAT–Luc reporter plasmid was a gift from Peter Kao and con-
tains three copies of the NFAT binding site (–286 to –257 of the
human IL-2 gene) linked to the human IL-2 promoter (–72 to +47)
driving luciferase [28]. The NFAT–Cre plasmid was constructed by
combining a blunted Hind III to Dra III fragment from pCMVCre
(pLM208), containing the Cre coding region and a polyadenylation
signal, with a blunted Hind III to EcoRI fragment from the plasmid
NFAT–SEAP [29] containing the NFAT-responsive elements and IL-2
promoter described above. Subsequently, a neomycin resistance cas-
sette (Nde I to BamH I fragment from pSV2neo [30] was inserted into
NFAT–Cre to form NFAT–Cre–neo. 
Plasmid MMTV–Luc (pLM253) was constructed as described previ-
ously [12]. To construct MMTV–Cre (pLM269), the MMTV–Luc
plasmid was digested with Nco I/Sal I to remove the luciferase gene
and religated. The resulting plasmid was digested with XhoI/Hind III,
and ligated to an XhoI/Hind III restriction fragment containing the Cre
gene from pBS185 [31]. 
Plasmid 6CRE–Luc (6CRE–TK–Luc/Hyg) was constructed as
described previously [32]. To construct 6CRE-Cre (pLM266), the Cre
gene was amplified from pBS39 [33] and cloned into the XhoI/Hind III
sites of a derivative of 6CRE-Luc in which a XhoI linker was inserted at
the unique SmaI site. 
Cell growth, transfection and isolation of stable transfectants
CHO-K1 (ATCC, Rockville, MD) or Jurkat cells were incubated at 37°C
under 5% CO2 and cultured in growth medium consisting of Dulbecco’s
modified Eagle medium/Nutrient Mixture F12 (D-MEM/F12) containing
5% FetalClone II (Hyclone, Logan, UT) or RPMI 1640 containing 10%
fetal bovine serum (FBS) respectively, supplemented with 100 U/ml
penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml amphotericin B. To
isolate CHO transfectants, 107 cells suspended in 0.8 ml of D-
MEM/F12 were combined with 20 µg each of plasmid DNA in a 0.4 cm
cuvette and electroporated with a BioRad Gene Pulser set at 400 V and
250 µF. To isolate Jurkat stable transfectants, 3 × 107 cells were sus-
pended in 0.3 ml of RPMI 1640 containing 10% FBS and combined
with 20 µg linearized plasmid DNA in a 0.4 cm cuvette. Cells were elec-
troporated as above except with 250 V and 960 µF settings. Cells were
grown for 48 h before selecting with 1 mg/ml G418, 10 µg/ml
puromycin, or 800 U/ml hygromycin. After 10 days of selection, the pop-
ulation was cloned by limiting dilution or by a FACS into wells of 96-well
master plates. Clones were grown in the presence of G418 and
puromycin, and replica plated to wells of two 96-well black-view bottom
plates (Packard, Meriden, CT). Clones expressing Cre were always
grown in medium containing puromycin to prevent unregulated recombi-
nation. To assay for luciferase inducibility in individual clones, cells were
washed and incubated in growth medium lacking puromycin in the pres-
ence or absence of stimulating agent(s) for the indicated times. 
Transient transfections 
Jurkat cells were transiently transfected by electroporation essentially as
previously described [34] using 4 µg each plasmid with 1.5 × 107 cells
in 0.3 ml growth medium. After electroporation, cells were recovered for
18–24 h in 8 ml growth medium before stimulations with ionomycin
(2 µM), PMA (20 ng/ml), or both. CHO cells were transiently transfected
by lipid-mediated transfection as previously described [12] using the
β-galactosidase reporter plasmid, pCH110, as an internal control.
Luciferase assays were performed as described above and β-galactosi-
dase assays were performed as previously described [12]. Luciferase
activity in each well is normalized to the β-galactosidase activity in that
well by dividing the luciferase activity by the β-galactosidase activity.
Luciferase assay
To measure luciferase activity in stable clones, 5 × 104 CHO cells or
2 × 105 Jurkat cells were added to each well of a 96-well black-view
bottom plate and incubated in growth medium lacking puromycin as
indicated. Each well was washed and filled with 100 µl of DMEM/F12
medium lacking phenol red and 100 µl of LucLite reagent (Packard,
Meriden, CT). The plate was agitated for a few minutes and lumines-
cence was measured in a 96-well TopCount scintillation counter
(Packard). Luciferase activity was measured as luminescent counts
per second (cps).
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